RENX — Renalytix Income Statement
0.000.00%
Last trade - 00:00- £26.50m
- £25.38m
- $2.29m
Annual income statement for Renalytix, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 1.49 | 2.97 | 3.4 | 2.29 |
| Cost of Revenue | |||||
| Gross Profit | — | 0.687 | 0.918 | 0.701 | 0.213 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 11.1 | 35.8 | 60.3 | 45.8 | 43.3 |
| Operating Profit | -11.1 | -34.3 | -57.4 | -42.4 | -41 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -10.6 | -35.8 | -49.6 | -46.2 | -45.5 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -9.25 | -31 | -56.7 | -46.2 | -45.5 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -9.25 | -31 | -56.7 | -46.2 | -45.5 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -9.25 | -31 | -56.7 | -46.2 | -45.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.157 | -0.419 | -0.779 | -0.562 | -0.323 |